ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
17 announcements with these filters
Jasti group entities transferred 51,00,000 Cohance shares to Jasub Property Holdings LLP via inter-se block deals. Combined group holding remains 6.36%.
Cohance Lifesciences disclosed that USFDA issued the Establishment Inspection Report for its Pashamylaram facility, classifying the inspection as Voluntary Action Indicated. The inspection is now concluded.
Cohance Lifesciences appointed Kuber Jagdale as Executive Director for 60 months, effective 7 November 2026. He brings over three decades of pharmaceutical manufacturing and operations experience.
Q2 revenue rose about 13% QoQ to ₹477 Cr and adjusted EBITDA reached about ₹46 Cr (~10% margin), but both remain below last year. H2 YoY growth is promised without figures, and FY27 specialty chemicals guidance was cut to decline.
Cohance Lifesciences issued a press release on its unaudited Q2 and H1 FY27 results. It reported lower year-on-year revenue and an expected stronger second half.
Q2FY27 revenue INR 4,766 Mn, down 14.2% YoY but up 12.9% QoQ. Adjusted EBITDA margin 9.6%, adjusted PAT INR 74 Mn back positive. Strategy centres on One Cohance integration and H2 recovery.
Cohance Lifesciences Ltd reported revenue from operations of ₹476.6 Cr (-14.2% YoY) and net profit of ₹2.3 Cr (-96.5% YoY) for Q2 FY27.
Cohance Lifesciences disclosed a TGPCB closure order halting manufacturing at its Suryapet site after an industrial accident. The financial impact cannot yet be quantified.
Cohance Lifesciences will hold a board meeting on 6 November 2026 to approve Q2 and half-year results. The trading window stays closed until 9 November 2026.
Cohance Lifesciences Ltd filed its quarterly shareholding pattern under Regulation 31(1)(b), disclosing promoter and public shareholding data as of September 30, 2026.
Cohance Lifesciences received Central Government approval for the appointment of Mr. Umang Vohra as Chairman and Group CEO.
Cohance Lifesciences Ltd. approved the grant of 2,60,194 stock options under ESOP 2026 and 6,14,594 stock options under ESOP 2023 to eligible employees.
Cohance Lifesciences appointed Mr. Abhimanyu Ojha as the new Chief Financial Officer and Key Managerial Personnel, effective October 12, 2026.
Cohance Lifesciences received a voluntary ESG Rating of Crisil ESG 61 (Strong) from Crisil ESG Ratings. No capital or business event is involved.
Cohance Lifesciences completed a USFDA inspection at its Jaggaiahpet API facility, receiving a Form 483 with five observations. The company has initiated corrective and preventive actions.
Cohance Lifesciences invested USD 10 million (₹95 Crore) into its subsidiary NJ Bio, Inc. to subscribe for new Compulsorily Convertible Preferred Stock.
Cohance Lifesciences Limited conducted its 8th Annual General Meeting on 17 September 2026. All resolutions proposed in the notice were passed by the requisite majority.